Trial DesignRationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial
Section snippets
Background
Oral P2Y12 inhibitors are key secondary prevention medications after coronary stent implantation or acute coronary syndromes (ACSs). Ticagrelor, unlike other oral P2Y12 inhibitors, has been associated with off-target effects, such as an improvement in endothelial function assessed by peripheral arterial tonometry, as recently reported in a nonrandomized trial.1 Moreover, in a recent randomized trial of 60 ACS patients, 30-day ticagrelor administration was shown to increase reactive hyperemia
Study design and population
The HI-TECH study (ClinicalTrial.gov NCT02587260) is a multinational, randomized, open-label, crossover study with a Latin squares design conducted at 5 European sites and including 54 patients, aiming to assess whether ticagrelor, as compared with both clopidogrel and prasugrel, improves endothelial function. Eligible patients were older than 18 years treated for an ACS, including ST-segment elevation myocardial infarction, non–ST-segment elevation myocardial infarction, or unstable angina, at
Conclusions
The HI-TECH study is the first randomized, crossover study aiming to ascertain whether ticagrelor, when administered at approved regimen in post-ACS patients, improves endothelial function as compared with both clopidogrel and prasugrel. The first patient was randomized on December 2015 and the last on October 2016 with a total of 54 patients. The last follow-up visit was performed on February 2017 and the final results are expected in the third quarter of 2017.
Disclosures
Salvatore Brugaletta received lectures fees from AstraZeneca, Abbott, and Boston, and has received institutional research grant from AstraZeneca. Sergio Leonardi received personal fees from AstraZeneca, The Medicine Company, Merck, Daiichi Sankyo, and Ely Lilly, and institutional research grants from AstraZeneca and Daiichi Sankyo. K. Stephan Windecker received research contracts to the institution from Abbott, Biotronik, Boston Scientific, Medtronic, Edwards Lifesciences, and St Jude. Marco
Contributorship
M.V. designed the study and obtained funding. M.V. and S.A. contributed to protocol development. M.V. and S.A. actively participated in the writing of the manuscript. D.H. contributed to the statistical analysis and actively participated in the writing of the statistical sections of the manuscript. All authors critically reviewed the manuscript and approved the final version.
References (41)
- et al.
Ticagrelor improves peripheral arterial function in acute coronary syndrome patients: relationship with adenosine plasma level
J Am Coll Cardiol
(2016) - et al.
Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia
J Am Coll Cardiol
(2004) - et al.
Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude
Am Heart J
(2003) - et al.
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance
J Am Coll Cardiol
(2014) - et al.
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome
J Am Coll Cardiol
(2014) - et al.
Ticagrelor induces adenosine triphosphate release from human red blood cells
Biochem Biophys Res Commun
(2012) - et al.
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats
Thromb Res
(2012) - et al.
Variability of peripheral arterial tonometry in the measurement of endothelial function in healthy men
Clin Cardiol
(2009) - et al.
Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents
J Pediatr
(2009) - et al.
Reproducibility of the flow-mediated dilation response to acute exercise in overweight men
Ultrasound Med Biol
(2007)
Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation
J Am Coll Cardiol
Oxidative-nitrosative stress and systemic vascular function in highlanders with and without exaggerated hypoxemia
Chest
Systemic vascular dysfunction in patients with chronic mountain sickness
Chest
Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine
Lancet
Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD
Thromb Res
An ELISA for the quantitation of von Willebrand factor: osteoprotegerin complexes in plasma
Thromb Res
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome
Cardiology
Lack of evidence for deterioration in endothelial function following ticagrelor treatment cessation
Curr Vasc Pharmacol
Human endothelial dysfunction: EDRFs
Pflugers Arch
Human endothelial dysfunction: EDCFs
Pflugers Arch
Cited by (0)
NCT02587260